We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Lorlatinib - PF-06463922

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03127618
Expanded Access Status : Approved for marketing
First Posted : April 25, 2017
Last Update Posted : May 15, 2020
Information provided by (Responsible Party):

Tracking Information
First Submitted Date April 20, 2017
First Posted Date April 25, 2017
Last Update Posted Date May 15, 2020
Descriptive Information
Brief Title Lorlatinib - PF-06463922
Official Title Not Provided
Brief Summary Lorlatinib expanded access program
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Not Provided
Intervention Drug: Lorlatinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Approved for marketing
Eligibility Criteria

Inclusion Criteria:

  • Adult, Senior

Exclusion Criteria:


Sex/Gender Not Provided
Ages 18 Years and older   (Adult, Older Adult)
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03127618
Other Study ID Numbers B746
Current Responsible Party Pfizer
Original Responsible Party Same as current
Current Study Sponsor Pfizer
Original Study Sponsor Same as current
Collaborators Not Provided
Investigators Not Provided
PRS Account Pfizer
Verification Date May 2020